Managing rheumatic diseases during childbearing years requires careful planning. Specifically, doctors often recommend bDMARDs in pregnancy to maintain disease control and protect maternal health. Therefore, ensuring clinical remission before conception improves overall fetal outcomes. Most experts agree that uncontrolled maternal inflammation carries higher risks than biological therapy. Consequently, healthcare providers prioritize treatment continuity for stable patients.
Safety Standards for bDMARDs in Pregnancy
Tumour necrosis factor (TNF) inhibitors currently possess the most extensive safety data. These large monoclonal antibodies cannot cross the placenta during the first trimester. Because organogenesis occurs early, teratogenicity remains highly unlikely for these patients. Furthermore, clinical trials show no significant increase in congenital malformations compared to the general population. However, data for newer biologic agents with different targets are still emerging. Therefore, clinicians must assess each patient individually to determine the safest course of action.
Lactation and Postpartum Management
Fortunately, most biologics are compatible with breastfeeding according to recent medical guidelines. These medications are large protein molecules that rarely enter breast milk. Even if they do, the infant’s digestive tract likely destroys these proteins before absorption. Additionally, maintaining maternal health during the postpartum period prevents painful disease flares. Mothers should not feel discouraged from nursing while continuing their necessary biological therapy.
Neonatal Vaccination After bDMARD Exposure
In utero exposure to biologics may temporarily influence the baby’s developing immune system. Consequently, doctors recommend delaying live-attenuated vaccines for infants exposed in the third trimester. Most protocols suggest waiting six months before administering the rotavirus or BCG vaccine. In contrast, inactivated vaccines are safe and follow the standard pediatric schedule. Finally, clear communication between rheumatologists and pediatricians ensures a safe vaccination timeline.
Frequently Asked Questions
Q1: Are TNF inhibitors safe to use during the first trimester?
Yes, TNF inhibitors are considered safe during early pregnancy. Since these large molecules do not cross the placenta during organogenesis, the risk of structural birth defects remains very low.
Q2: Can I continue my biological therapy while breastfeeding?
Most guidelines confirm that biologics are compatible with breastfeeding. These medications are large proteins that do not enter breast milk in significant amounts and are unlikely to be absorbed by the infant.
References
- Siegel CH et al. Biologic Disease-Modifying Antirheumatic Drug Use During Pregnancy and Lactation. Obstet Gynecol. 2026 Feb 19. doi: 10.1097/AOG.0000000000006193. PMID: 41712933.
- Rüegg L et al. EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 update. Ann Rheum Dis. 2025 Jun;84(6):910-926.
- Sammaritano LR et al. 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis Rheumatol. 2020;72(4):529-556.